The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy
Abstract
The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3′-azido-3′-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4 + HeLa cells. Fifty percent inhibitory dose (ID 50 ) values of 18 isolates from untreated individuals ranged between 0.01 μ M and 0.05 μ M . In contrast, most isolates from patients who had received zidovudine for 6 months or more exhibited decreased sensitivity characterized by changes in ID 50 or ID 95 values (or both), with isolates from several patients (5/15) showing 100-fold increases in ID 50 . The latter isolates were also insensitive to 3′-azido-2′,3′-dideoxyuridine; however, the isolates were still sensitive to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-2′,3′-didehydrothymidine, or phosphonoformate. It cannot be determined from this small sample of patients whether development of a less sensitive virus phenotype results in clinical resistance. Appearance of such variants was not associated with a consistent increase in viral p24 concentrations in patient plasma and did not herald any sudden deterioration in clinical status. More extensive studies are required to determine the clinical significance. Thus, it would be premature to alter any treatment protocols for HIV-infected individuals at present.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a clinical trial, its dramatic short-term effects in delaying the death of AIDS patients (109) led to its rapid approval for use, although the virus rebounded after a few months due to the appearance of mutations in RT that render it AZT resistant (110).”
From The Discovery of Reverse Transcriptase (2016) · cites this paper as [110]
Citations
Cites
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170401 · Cited by 2,995
Self-citationThe Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Richman, D. D., Fischl, M. A., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Hirsch, M. S., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170402 · Cited by 1,199
Self-citationInfection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay
Harada, S., Koyanagi, Y., & Yamamoto, N. (1985) · Science · doi:10.1126/science.2992081 · Cited by 857
Schmitt, F. A., Bigley, J. W., McKinnis, R., Logue, P. E., Evans, R. W., Drucker, J. L., & The AZT Collaborative Working Group* (1988) · New England Journal of Medicine · doi:10.1056/nejm198812153192404 · Cited by 396
Klecker, R. W., Collins, J. M., Yarchoan, R., Thomas, R., Jenkins, J. F., Broder, S., & Myers, C. E. (1987) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1987.49 · Cited by 381
Site-specific mutagenesis of AIDS virus reverse transcriptase
Larder, B. A., Purifoy, D. J. M., Powell, K. L., & Darby, G. (1987) · Nature · doi:10.1038/327716a0 · Cited by 312
Self-citationDevelopment of a sensitive quantitative focal assay for human immunodeficiency virus infectivity
Chesebro, B., & Wehrly, K. (1988) · Journal of Virology · doi:10.1128/jvi.62.10.3779-3788.1988 · Cited by 304
Field, H. J., & Darby, G. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.17.2.209 · Cited by 242
Self-citationISOLATION AND CHARACTERISATION OF RESISTANT HERPES SIMPLEX VIRUS AFTER ACYCLOVIR THERAPY
Burns, W., Santos, G., Saral, R., Laskin, O., Lietman, P., Mclaren, C., & Barry, D. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91620-8 · Cited by 240
Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance
Darby, G., Field, H. J., & Salisbury, S. A. (1981) · Nature · doi:10.1038/289081a0 · Cited by 204
Self-citation
Cited by
Items 401–500 of 1,000
Synthesis and anti-HIV activity of pyrrolo-[1,2-d]-(1,4)-benzodiazepin-6-ones
Lucca, G. V. D., & Otto, M. J. (1992) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)80447-3 · Cited by 62
Whittington, R., & Brogden, R. N. (1992) · Drugs · doi:10.2165/00003495-199244040-00009 · Cited by 62
Bollinger, R. C., Kline, R. L., Francis, H. L., Moss, M. W., Bartlett, J. G., & Quinn, T. C. (1992) · The Journal of Infectious Diseases · doi:10.1093/infdis/165.5.913 · Cited by 62
KOOT, M., Schellekens, P. T. A., Mulder, J. W., Lange, J. M. A., Roos, M. T. L., Coutinho, R. A., Tersmette, M., & Miedema, F. F. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/168.3.733 · Cited by 62
Saha, S., Galhardi, L. C. F., Yamamoto, K. A., Linhares, R. E. C., Bandyopadhyay, S. S., Sinha, S., Nozawa, C., & Ray, B. (2010) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2010.08.011 · Cited by 61
Borrow, P., & Shaw, G. M. (1998) · Immunological Reviews · doi:10.1111/j.1600-065x.1998.tb01206.x · Cited by 61
Clinical toxicity of antiretroviral nucleoside analogs
Styrt, B. A., Piazza-Hepp, T. D., & Chikami, G. K. (1996) · Antiviral Research · doi:10.1016/0166-3542(96)85209-0 · Cited by 61
Hsu, M. C., Dhingra, U., Earley, J. V., Holly, M., Keith, D. E., Nalin, C. M., Richou, A. R., Schutt, A., Tam, S. Y. K., & Potash, M. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6395 · Cited by 61
Drosopoulos, W. C., & Prasad, V. R. (1996) · Journal of Virology · doi:10.1128/jvi.70.7.4834-4838.1996 · Cited by 61
Pahwa, S. G., Chirmule, N. B., Leombruno, C., Lim, W. L., Harper, R., Bhalla, R., Pahwa, R., NELSON, R. P., & Good, R. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7532 · Cited by 61
Sebire, K., McGavin, K., Land, S., Middleton, T., & Birch, C. J. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.2.493-498.1998 · Cited by 60
Cherrington, J. M., Mulato, A. S., Fuller, M. D., & Chen, M. S. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.9.2212 · Cited by 60
Lennerstrand, J., Hertogs, K., STAMMERS, D. K., & Larder, B. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.7202-7205.2001 · Cited by 60
Self-citationEron, J. J., Chow, Y.-K., Caliendo, A. M., Videler, J. A., Devore, K. M., Cooley, T. P., Liebman, H. A., Kaplan, J. C., Hirsch, M., & D’Aquila, R. T. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.7.1480 · Cited by 60
Chronic Infectious Disease and the Future of Health Care Delivery
Farmer, P. E. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1310472 · Cited by 59
Overview of the Preclinical Development of an Antiretroviral Drug, 2′,3′-Dideoxyinosine
McGowan, J. J., Tomaszewski, J. E., Cradock, J. C., Hoth, D. F., Grieshaber, C. K., Broder, S. E., & Mitsuya, H. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_5.s513 · Cited by 59
Balzarini, J. M., Pérez‐Pérez, M., San‐Félix, A., Velázquez, S., Camarasa, M., & Clercq, E. D. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.5.1073 · Cited by 59
Canard, B., Sarfati, S. R., & Richardson, C. C. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14596 · Cited by 59
Ogino, M., Dankner, W. M., & Spector, S. A. (1993) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)81529-x · Cited by 59
NAIR, V., Clair, M. H. S., Reardon, J. E., Krasny, H. C., Hazen, R. J., Paff, M. T., Boone, L. R., Tisdale, M., Nájera, I., & Dornsife, R. E. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.9.1993 · Cited by 59
Nolan, M. L., Fowler, M. G., & MOFENSON, L. M. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200206010-00011 · Cited by 59
Davey, R. T., Davey, V. J., Metcalf, J., Zurlo, J. J., Kovacs, J. A., Falloon, J., Polis, M. A., Zunich, K. M., Masur, H., & Lane, H. C. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/164.1.43 · Cited by 59
Gao, Q., Gu, Z., Hiscott, J. B., Dionne, G., & Wainberg, M. A. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.1.130 · Cited by 59
Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors
Vasudevachari, M. B., Battista, C. D., Lane, H. C., Psallidopoulos, M. C., Zhao, B., Cook, J., Palmer, J. R., Romero, D. L., Tarpley, W. G., & Salzman, N. P. (1992) · Virology · doi:10.1016/0042-6822(92)91213-e · Cited by 59
Kageyama, S., Weinstein, J. N., Shirasaka, T., Kempf, D. J., Norbeck, D. W., PLATTNER, J. J., Erickson, J. W., & Mitsuya, H. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.5.926 · Cited by 59
López‐Galíndez, C., Rojas, J. M., Nájera, R., Richman, D. D., & Perucho, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.10.4280 · Cited by 59
Self-citationFeder, A. F., Harper, K. N., Brumme, C. J., & Pennings, P. S. (2021) · eLife · doi:10.7554/elife.69032 · Cited by 58
Cho, Y.-K., Sung, H., Lee, H. J., Joo, C. H., & Cho, G.-J. (2001) · International Immunopharmacology · doi:10.1016/s1567-5769(01)00061-3 · Cited by 58
Antiretroviral therapy: reverse transcriptase inhibition
Connolly, K. J., & Hammer, S. M. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.2.245 · Cited by 58
Iglesias-Ussel, M. D., Casado, C., Yuste, E., Olivares, I., & López‐Galíndez, C. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-1-93 · Cited by 57
Robinson, W. E. (1998) · Antiviral Research · doi:10.1016/s0166-3542(98)00037-0 · Cited by 57
The Global Status of Resistance to Antiretroviral Drugs
Vella, S., & Palmisano, L. (2005) · Clinical Infectious Diseases · doi:10.1086/430784 · Cited by 57
Staszewski, S., Massari, F. E., Kober, A., Gohler, R., Durr, S., Anderson, K. W., Schneider, C. L., Waterbury, J. A., Bakshi, K. K., Taylor, V. I., et al. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.5.1159 · Cited by 57
JACOBSSON, B., Britton, S., He, Q., Karlsson, A., & Eriksson, S. (1995) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1995.11.805 · Cited by 57
Rooke, R., Parniak, M. A., Tremblay, M., Soudeyns, H., Li, X. G., Gao, Q., Yao, X., & Wainberg, M. A. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.5.988 · Cited by 57
Bolon, P. J., Wang, P., Chu, C. K., Gosselin, G., Vivet‐Boudou, V., Pierra, C., Mathé, C., Imbach, J., Faraj, A., Elalaoui, A., et al. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(96)00293-4 · Cited by 57
Margot, N., Enejosa, J., Cheng, A., Miller, M. D., & McColl, D. J. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181b05f7c · Cited by 56
Richman, D. D. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90414-9 · Cited by 56
Self-citationStructure−Activity Relationships of 2‘-Fluoro-2‘,3‘-unsaturated d -Nucleosides as Anti-HIV-1 Agents
Lee, K., Choi, Y., Gumina, G., Zhou, W., Schinazi, R. F., & Chu, C. K. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010418n · Cited by 56
CD8+ Lymphocyte Responses to Antiretroviral Therapy of HIV Infection
Carr, A. D., Emery, S., Kelleher, A. D., Law, M. G., & Cooper, D. A. (1996) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199612010-00004 · Cited by 56
Sczakiel, G., Oppenländer, M., Rittner, K., & Pawlita, M. (1992) · Journal of Virology · doi:10.1128/jvi.66.9.5576-5581.1992 · Cited by 56
Katsuraya, K., Nakashima, H., Yamamoto, N., & Uryu, T. (1999) · Carbohydrate Research · doi:10.1016/s0008-6215(98)00315-2 · Cited by 55
Dose-Related Activity Of Stavudine In Patients Infected With Human Immunodeficiency Virus
Petersen, E. A., Ramirez-Ronda, C. H., Hardy, W. D., Schwartz, R., Sacks, H. S., Follansbee, S., Peterson, D. M., Cross, A. P., Anderson, R. E., & Dunkle, L. M. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.supplement_2.s131 · Cited by 55
Rumi, M. G., Ninno, E. D., Parravicini, M. L., Romeo, R., Soffredini, R., Donato, M. F., Wilber, J. C., Russo, A., & Colombo, M. G. (1996) · Hepatology · doi:10.1002/hep.510240609 · Cited by 55
Recent trends in HIV-1 drug resistance
Siliciano, J. D., & Siliciano, R. F. (2013) · Current Opinion in Virology · doi:10.1016/j.coviro.2013.08.007 · Cited by 54
The Discovery and Development of Antiretroviral Agents
Lange, J. M. A., & Ananworanich, J. (2013) · Antiviral Therapy · doi:10.3851/imp2896 · Cited by 54
Antiretroviral therapy for patients with HIV disease
Barry, M. G., Mulcahy, F. M., & Back, D. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00673.x · Cited by 54
Gao, Y., Fukuda, A., Katsuraya, K., Kaneko, Y., Mimura, T., Nakashima, H., & Uryu, T. (1997) · Macromolecules · doi:10.1021/ma961711d · Cited by 54
Role of lipid rafts in virus assembly and budding
Nayak, D. P., & Barman, S. (2002) · Advances in virus research · doi:10.1016/s0065-3527(02)58001-5 · Cited by 54
Zidovudine Toxicity: Clinical Features and Management
Rachlis, A., & Fanning, M. M. (1993) · Drug Safety · doi:10.2165/00002018-199308040-00005 · Cited by 54
Borroto–Esoda, K., & Boone, L. R. (1991) · Journal of Virology · doi:10.1128/jvi.65.4.1952-1959.1991 · Cited by 54
DRAANEN, N. A. V., Tisdale, M., Parry, N. R., Jansen, R., Dornsife, R. E., Tuttle, J. V., Averett, D. R., & Koszalka, G. W. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.868 · Cited by 54
Zidovudine Resistance of Human Immunodeficiency Virus
Richman, D. D. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_5.s507 · Cited by 54
Self-citationFactors influencing minority student decisions to consider a career in evolutionary biology
Mead, L. S., Clarke, J. B., Forcino, F. L., & Graves, J. L. (2015) · Evolution Education and Outreach · doi:10.1186/s12052-015-0034-7 · Cited by 53
Yin, P. D., Das, D., & Mitsuya, H. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6009-7 · Cited by 53
2′,3′-Dideoxyinosine in Patients with AIDS or AIDS-Related Complex
Dolin, R., Lambert, J. S., Morse, G. D., Reichman, R. C., Plank, C. S., Reid, J. E., Knupp, C., McLaren, C., & Pettinelli, C. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_5.s540 · Cited by 53
Evaluating Clinical Isolates for Their Phenotypic and Genotypic Resistance Against Anti-HIV Drugs
Vandamme, A., Witvrouw, M., Pannecouque, C. C., Balzarini, J. M., Laethem, K. V., Schmit, J., Desmyter, J., & Clercq, E. D. (2003) · Humana Press eBooks · doi:10.1385/1-59259-245-7:223 · Cited by 53
Chong, K. T. D., Pagano, P. J., & Hinshaw, R. R. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.2.288 · Cited by 53
Larder, B. A., Kohli, A., Bloor, S., Kemp, S. D., Harrigan, P. R., Schooley, R. T., Lange, J. M. A., Pennington, K. N., & Clair, M. H. S. (1996) · Journal of Virology · doi:10.1128/jvi.70.9.5922-5929.1996 · Cited by 53
Self-citationSei, S., Yang, Q., O’Neill, D., Yoshimura, K., Nagashima, K., & Mitsuya, H. (2000) · Journal of Virology · doi:10.1128/jvi.74.10.4621-4633.2000 · Cited by 53
In Vitro Antiviral Activity of Marine Sponges Collected Off Brazilian Coast
da Silva, A. C., Kratz, J. M., Farias, F. M., Henriques, A. T., dos Santos, J., Leonel, R. M. V., Lerner, C. B., Beatriz Mothes, B., Barardi, C. R. M., & Simões, C. M. O. (2006) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.29.135 · Cited by 52
Procedures for reliable estimation of viral fitness from time-series data
Bonhoeffer, S., Barbour, A. D., & de Boer, R. J. (2002) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2002.2097 · Cited by 52
Drusano, G. L., Yuen, G. J., Lambert, J. S., Seidlin, M., Dolin, R., & Valentine, F. T. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-7-562 · Cited by 52
Phenotypic and Genotypic HIV-1 Drug Resistance Assays Provide Complementary Information
Parkin, N. T., Chappey, C., Maroldo, L., Bates, M. P., Hellmann, N. S., & Petropoulos, C. J. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200210010-00002 · Cited by 52
Land, S., McGavin, C. H., Lucas, R., & Birch, C. (1992) · The Journal of Infectious Diseases · doi:10.1093/infdis/166.5.1139 · Cited by 52
The role of tumour necrosis factor‐α in acquired immunodeficiency syndrome
Odeh, M. (1990) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1990.tb00278.x · Cited by 52
Global analysis of HIV-1 dynamics with Hill type infection rate and intracellular delay
Bairagi, N., & Adak, D. (2014) · Applied Mathematical Modelling · doi:10.1016/j.apm.2014.03.010 · Cited by 51
Deep Sequencing of HIV: Clinical and Research Applications
Chabria, S., Gupta, S., & Kozal, M. J. (2014) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091212-153406 · Cited by 51
Codon 215 Mutations in Human Immunodeficiency Virus–Infected Pregnant Women
Kully, C., Yerly, S., Erb, P., Kind, C., Krautheim, A., Perrin, L. H., Rudin, C., & Study, T. S. C. `. A. P. (1999) · The Journal of Infectious Diseases · doi:10.1086/314615 · Cited by 51
Virus population dynamics, fitness variations and the control of viral disease: an update
Domingo, E., Más, A., Yuste, E., Pariente, N., Sierra, S., Gutiérrez‐Rivas, M., & Menéndez‐Arias, L. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8308-5_2 · Cited by 51
Kuppermann, B. D., Flores-Aguilar, M., Quiceno, J. I., Rickman, L. S., & Freeman, W. R. (1993) · Archives of Ophthalmology · doi:10.1001/archopht.1993.01090100067029 · Cited by 51
Hayashi, S., Fine, R. L., Chou, T., Currens, M. J., Broder, S., & Mitsuya, H. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.1.82 · Cited by 51
Koshida, R., Cox, S., Harmenberg, J., Gilljam, G., & Wahrén, B. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.12.2083 · Cited by 51
Boucher, C. A., van Leeuwen, R., Kellam, P., Schipper, P. J., Tijnagel, J. M. G. H., Lange, J. M. A., & Larder, B. A. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.7.1525 · Cited by 51
Self-citationShelton, M. J., O'Donnell, A. M., & Morse, G. D. (1992) · Annals of Pharmacotherapy · doi:10.1177/106002809202600511 · Cited by 51
Eriksson, B., CHU, C. K., & Schinazi, R. F. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.10.1729 · Cited by 51
Current Advances in the Diagnosis and Treatment of AIDS: An Introduction
Groopman, J. E. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.5.908 · Cited by 50
Antimicrobial applications of chitosan
Tachaboonyakiat, W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-08-100228-5.00009-2 · Cited by 50
Primary HIV-1 Strains Use Nef To Downmodulate HLA-E Surface Expression
Thans, T. V. S., Akko, J. I., Niehrs, A., García-Beltrán, W. F., Richert, L. E., Stürzel, C. M., Ford, C. T., Li, H. J., Ochsenbauer, C., Kappes, J. C., et al. (2019) · Journal of Virology · doi:10.1128/jvi.00719-19 · Cited by 50
Understanding transmitted HIV resistance through the experience in the USA
Taiwo, B. (2009) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2008.10.008 · Cited by 50
Domingo, E., Escarmís, C., Menéndez‐Arias, L., Perales, C., Herrera, M., Novella, I. S., & Holland, J. J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374153-0.00004-7 · Cited by 50
Moore, R. D., Creagh-Kirk, T., Keruly, J., Link, G., Wang, M. C., Richman, D., & Chaisson, R. E. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.151.5.981 · Cited by 50
Self-citationLewis, J. S., Terriff, C. M., Coulston, D. R., & Garrison, M. W. (1997) · Clinical Therapeutics · doi:10.1016/s0149-2918(97)80110-5 · Cited by 50
Chemotherapy of Human Immunodeficiency Virus Infections: Current Practice and Future Prospects
Hirsch, M. (1990) · The Journal of Infectious Diseases · doi:10.1093/infdis/161.5.845 · Cited by 50
Competitive inhibitors of human immunodeficiency virus reverse transcriptase
Schinazi, R. F. (1993) · Perspectives in Drug Discovery and Design · doi:10.1007/bf02171660 · Cited by 50
Zidovudine Induces the Expression of Cellular Resistance Affecting Its Antiviral Activity
DIANZANI, F., Antonelli, G., Turriziani, O., Riva, E., Simeoni, E., Signoretti, C., STROSSELLI, S., & Cianfriglia, M. (1994) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1994.10.1471 · Cited by 50
Borkow, G., Arion, D., Wainberg, M. A., & Parniak, M. A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.2.259 · Cited by 50
Suppression of HIV-1 viral replication and cellular pathogenesis by a novel p38/JNK kinase inhibitor
Muthumani, K., Wadsworth, S. A., Dayes, N. S., Hwang, D. S., Choo, A. Y., Abeysinghe, H. R., Siekierka, J. J., & Weiner, D. B. (2004) · AIDS · doi:10.1097/00002030-200403260-00004 · Cited by 49
Chen, M. S., Suttmann, R. T., Papp, E., Cannon, P. D., McRoberts, M. J., Bach, C., Copeland, W. C., & Wang, T. S. ‐. (1993) · Biochemistry · doi:10.1021/bi00074a011 · Cited by 49
Stefano, M. D., Sabri, F., Leitner, T., Svennerholm, B., Hagberg, L., Norkrans, G., & Chiodi, F. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.2.352-355.1995 · Cited by 49
Characterization of HIV-1 Strains Isolated from Patients Treated with TIBO R82913
Vandamme, A., Debyser, Z., Pauwels, R., de Vreese, K., Goubau, P., Youle, M. S., Gazzard, B., Stoffels, P., Cauwenbergh, G. F. M. J., Anné, J., et al. (1994) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1994.10.39 · Cited by 49
State-of-the-Art Conference on azidothymidine therapy for early HIV infection
(1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90347-g · Cited by 49
Krown, S. E., Paredes, J., & Myskowski, P. L. (1992) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30378-9 · Cited by 49
Williamson, S., Perry, S. M., Bustamante, C. D., Orive, M. E., Stearns, M. N., & Kelly, J. K. (2004) · Molecular Biology and Evolution · doi:10.1093/molbev/msi029 · Cited by 48
Peters, B. S., CHEINGSONG-POPOV, R., Callow, D., Foxall, R. B., Patou, G., Hodgkin, K., & Weber, J. N. (1997) · Journal of Infection · doi:10.1016/s0163-4453(97)92814-0 · Cited by 48
Treatment of HIV Infection: Tolerability of Commonly Used Antiretroviral Agents
Notermans, D. W., van Leeuwen, R., & Lange, J. M. A. (1996) · Drug Safety · doi:10.2165/00002018-199615030-00003 · Cited by 48
Anti-CD4 therapy for AIDS suggested by mathematical models
de Boer, R. J., & Boucher, C. A. (1996) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.1996.0133 · Cited by 48
Rolinski, B., Bogner, J. R., Sadri, I., Wintergerst, U., & Goebel, F. D. (1997) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199707010-00002 · Cited by 48
Prevention of HIV-1 Infection and Preservation of CD4 Function by the Binding of CPFs to gp120
Finberg, R. W., Diamond, D. C., Mitchell, D. B., Rosenstein, Y., Soman, G., Norman, T., Schreiber, S. L., & Burakoff, S. J. (1990) · Science · doi:10.1126/science.2115689 · Cited by 48
Metadata
- Authors
- Larder, B. A., Darby, G., & Richman, D. D.
- Affiliations
- Wellcome Trust (GB)
- University of California San Diego (US)
- ORCID
- Richman, Douglas D.
- Venue
- Science
- Published
- 1989-03-31
- Volume
- 243
- Issue
- 4899
- Pages
- 1731-1734
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2086462809
- Cited by
- 1,559
- References
- 22
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 3 · 2023: 10 · 2022: 12 · 2021: 8 · 2020: 9 · 2019: 12 · 2018: 6 · 2017: 13 · 2016: 16 · 2015: 10 · 2014: 21 · 2013: 13 · 2012: 16
- FWCI
- 157.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HB-6-7019)
- National Institute of Allergy and Infectious Diseases (AI-62548, AI-52578)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Keywords
- HIV drug resistance, zidovudine resistance, AIDS, AIDS-related complex, antiretroviral therapy, 2',3'-dideoxycytidine, phosphonoformate
- MeSH terms
- Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Drug Resistance, HeLa Cells, HIV, Humans, Microbial Sensitivity Tests, Phosphonoacetic Acid, Viral Plaque Assay, Retroviridae Proteins, Virus Replication, Zidovudine, Dideoxynucleosides, Zalcitabine, HIV Core Protein p24, Foscarnet, Reverse Transcriptase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.